Page last updated: 2024-12-07

6-chloropurine riboside

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

6-chloropurine riboside is a nucleoside analog with a chlorine atom at the 6-position of the purine base. It is synthesized by the reaction of 6-chloropurine with ribose. 6-chloropurine riboside has been shown to have antiviral and anticancer activity. It is an inhibitor of purine biosynthesis and is being studied as a potential treatment for viral infections and cancer. It has been shown to be effective against a variety of viruses, including herpes simplex virus and cytomegalovirus. 6-chloropurine riboside is also being investigated for its potential use in the treatment of autoimmune diseases and inflammatory disorders. 6-chloropurine riboside is studied because of its potential therapeutic applications. It is a potent antiviral agent and has shown promising results in preclinical studies. 6-chloropurine riboside is also being investigated for its potential to inhibit the growth of cancer cells.'

Cross-References

ID SourceID
PubMed CID93003
CHEMBL ID397974
SCHEMBL ID272122
MeSH IDM0081868

Synonyms (50)

Synonym
6-chloropurine riboside ,
5399-87-1
chloropurine riboside
6-chloro-9-beta-d-ribofuranosyl-9h-purine
einecs 217-904-8
brn 0040573
(2r,3r,4s,5r)-2-(6-chloropurin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
6-chloropurine riboside, 99%
CHEMBL397974
(2r,3r,4s,5r)-2-(6-chloropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(3s,2r,4r,5r)-5-(6-chloropurin-9-yl)-2-(hydroxymethyl)oxolane-3,4-diol
A814198
(2r,3r,4s,5r)-2-(6-chloro-9h-purin-9-yl)-5-(hydroxymethyl)-tetrahydrofuran-3,4-diol
einecs 226-438-4
4-26-00-01745 (beilstein handbook reference)
ai3-50219
9h-purine, 6-chloro-9-beta-d-ribofuranosyl-
AKOS015995297
c10h11cln4o4
6-chloro-9- -d-ribofuranosyl-9h-purine
(2r,3r,4s,5r)-2-(6-chloro-9h-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
(2r,3r,4s,5r)-2-(6-chloro-9h-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
AS-2050
6-chloropurineriboside
AKOS015896897
6-chloropurine-9-beta-d-ribofuranoside
6-chloropurine-9-?-d-ribofuranoside
HG1394
6-chloropurine-d-riboside
6-chloro-6-deaminoadenosine
6-chloropurine-9-|a-d-ribofuranoside
SCHEMBL272122
XHRJGHCQQPETRH-KQYNXXCUSA-N
6-chloro-9-(beta-d-ribofuranosyl)-purine
6-chloro-9-beta-d-ribofuranosylpurine
6-chloro-9(beta-d-ribofuranosyl)-purine
6-chlorpurine riboside
AM83942
AC-8214
BBL102796
STL556603
6-chloro-9-(beta-d-ribofuranosyl)-9h-purine
6-chloro-6-deoxyinosine
6-chloropurine 9-beta-d-ribofuranoside
A852095
(2r,3r,4s,5r)-2-(6-chloro-9h-purin-9-yl)-5-(hydroxymethyl)-tetrahydrofuran-3,4-diol;(2r,3r,4s,5r)-2-(6-chloro-9h-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
EN300-190575
DTXSID001313678
PD164076
Z1741975385

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" 9-beta-D-Ribofuranosylpurine-6-carboxamide (6a), the corresponding 6-thiocarboxamide (7b), and 4-amino-8-(beta-D-ribofuranosylamino)pyrimido[5,4-d]pyrimidine (8) showed significant in vitro antiviral activity at nontoxic dosage levels."( Synthesis and antiviral activity of certain 9-beta-D-ribofuranosylpurine-6-carboxamides.
Madsen, RD; Mancuso, RW; North, JA; Ogden, JR; Revankar, GR; Robins, RK; Rousseau, RJ; Stephen, EL; Westover, JD, 1981
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (27)

Assay IDTitleYearJournalArticle
AID99698In vitro antiviral activity against HSV-1 virus in human laryngeal epithelioma cell line / 1000 toxic level1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Synthesis and antiviral activity of certain 9-beta-D-ribofuranosylpurine-6-carboxamides.
AID584546Inhibition of inosine/L-alanine-induced Bacillus anthracis Sterne 34F2 spore germination pretreated for 15 mins before inosine/L-alanine challenge2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Testing nucleoside analogues as inhibitors of Bacillus anthracis spore germination in vitro and in macrophage cell culture.
AID584547Antibacterial activity against Bacillus anthracis Sterne 34F2 infected in mouse J774A.1 cells assessed as protection against bacteria-induced cytotoxicity using propidium iodide staining after 3 hrs measured every hours for up to 7 hrs2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Testing nucleoside analogues as inhibitors of Bacillus anthracis spore germination in vitro and in macrophage cell culture.
AID290454Antiviral activity against SARS-CoV Frankfurt1 in Vero E6 cells at 20 uM by yeild reduction assay2007Bioorganic & medicinal chemistry letters, May-01, Volume: 17, Issue:9
Synthesis and biological evaluation of nucleoside analogues having 6-chloropurine as anti-SARS-CoV agents.
AID85569Concentration required to inhibit HSV type 1 strain HF induced cytopathogenic affects by 50%1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Synthesis and antiviral activity of carbocyclic analogues of 2'-deoxyribofuranosides of 2-amino-6-substituted-purines and of 2-amino-6-substituted-8-azapurines.
AID217252In vitro antiviral activity against parainfluenza type 3(para 3) virus was determined in african green monkey kidney (vero,V) expressed as virus rating. Toxic level(1000 ug/mL)1982Journal of medicinal chemistry, Nov, Volume: 25, Issue:11
Synthesis and antiviral activity of certain carbamoylpyrrolopyrimidine and pyrazolopyrimidine nucleosides.
AID217834Concentration required to inhibit vaccinia virus induced cytopathogenic affects by 50%1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Synthesis and antiviral activity of carbocyclic analogues of 2'-deoxyribofuranosides of 2-amino-6-substituted-purines and of 2-amino-6-substituted-8-azapurines.
AID290451Antiviral activity against SARS-CoV Frankfurt1 in Vero E6 cells by plaque reduction assay2007Bioorganic & medicinal chemistry letters, May-01, Volume: 17, Issue:9
Synthesis and biological evaluation of nucleoside analogues having 6-chloropurine as anti-SARS-CoV agents.
AID301327Antiviral index, ratio of CC50 for Huh7 cells to EC50 for HCV replication2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
5'-O-masked 2'-deoxyadenosine analogues as lead compounds for hepatitis C virus (HCV) therapeutic agents.
AID99702In vitro antiviral activity against Para 3 virus in human laryngeal epithelioma cell line / 1000 toxic level1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Synthesis and antiviral activity of certain 9-beta-D-ribofuranosylpurine-6-carboxamides.
AID217259In vitro antiviral activity against vaccinia(VV) virus was determined in african green monkey kidney (vero,V) expressed as virus rating. Toxic level(1000 ug/mL)1982Journal of medicinal chemistry, Nov, Volume: 25, Issue:11
Synthesis and antiviral activity of certain carbamoylpyrrolopyrimidine and pyrazolopyrimidine nucleosides.
AID290452Cytotoxicity against Vero E6 cells2007Bioorganic & medicinal chemistry letters, May-01, Volume: 17, Issue:9
Synthesis and biological evaluation of nucleoside analogues having 6-chloropurine as anti-SARS-CoV agents.
AID216948In vitro antiviral activity against VSV virus in (vero) V cells of african green monkey kidney1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Synthesis and antiviral activity of certain 9-beta-D-ribofuranosylpurine-6-carboxamides.
AID216945In vitro antiviral activity against V V virus in (vero) V cells of african green monkey kidney1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Synthesis and antiviral activity of certain 9-beta-D-ribofuranosylpurine-6-carboxamides.
AID99709In vitro antiviral activity against VSV virus in human laryngeal epithelioma cell line / 1000 toxic level1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Synthesis and antiviral activity of certain 9-beta-D-ribofuranosylpurine-6-carboxamides.
AID85703In vitro antiviral activity in secondary cultures of rabbit kidney cells infected with HSV type 1 strain HF1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Synthesis and antiviral activity of carbocyclic analogues of 2'-deoxyribofuranosides of 2-amino-6-substituted-purines and of 2-amino-6-substituted-8-azapurines.
AID99704In vitro antiviral activity against V V virus human laryngeal epithelioma cell line / 1000 toxic level1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Synthesis and antiviral activity of certain 9-beta-D-ribofuranosylpurine-6-carboxamides.
AID99573In vitro antiviral activity against COXB1 virus in human laryngeal epithelioma cell line / 1000 toxic level1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Synthesis and antiviral activity of certain 9-beta-D-ribofuranosylpurine-6-carboxamides.
AID301326Cytotoxicity against Huh7 cells by XTT assay2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
5'-O-masked 2'-deoxyadenosine analogues as lead compounds for hepatitis C virus (HCV) therapeutic agents.
AID217966In vitro for antiviral activity in secondary cultures of rabbit kidney cells infected with vaccinia virus1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Synthesis and antiviral activity of carbocyclic analogues of 2'-deoxyribofuranosides of 2-amino-6-substituted-purines and of 2-amino-6-substituted-8-azapurines.
AID584550Cytotoxicity against mouse J774A1 cells2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Testing nucleoside analogues as inhibitors of Bacillus anthracis spore germination in vitro and in macrophage cell culture.
AID301325Inhibition of HCV replication in Huh7 cells after 48 hrs by luciferase assay2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
5'-O-masked 2'-deoxyadenosine analogues as lead compounds for hepatitis C virus (HCV) therapeutic agents.
AID217247In vitro antiviral activity against herpes simplex type 1 (HSV-1) virus was determined in african green monkey kidney (vero,V) expressed as virus rating. Toxic level(1000 ug/mL)1982Journal of medicinal chemistry, Nov, Volume: 25, Issue:11
Synthesis and antiviral activity of certain carbamoylpyrrolopyrimidine and pyrazolopyrimidine nucleosides.
AID228918Molar potency ratio was evaluated1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Dog coronary artery adenosine receptor: structure of the N6-alkyl subregion.
AID216939In vitro antiviral activity against HSV-1 virus in (vero) V cells of african green monkey kidney1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Synthesis and antiviral activity of certain 9-beta-D-ribofuranosylpurine-6-carboxamides.
AID216824In vitro antiviral activity against COXB1 virus in (vero) V cells of african green monkey kidney1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Synthesis and antiviral activity of certain 9-beta-D-ribofuranosylpurine-6-carboxamides.
AID290453Selectivity index, ratio of CC50 for Vero E6 cells to IC50 for SARS-CoV Frankfurt12007Bioorganic & medicinal chemistry letters, May-01, Volume: 17, Issue:9
Synthesis and biological evaluation of nucleoside analogues having 6-chloropurine as anti-SARS-CoV agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (53.85)18.7374
1990's1 (7.69)18.2507
2000's3 (23.08)29.6817
2010's2 (15.38)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.87 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.28 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]